|
HCV Genotype 1 Viral Loads Decline
A six-month follow-up to Intercell's Phase II trial of their Hepatitis C vaccine with a topical toll-like receptor agonist showed a significant reduction in viral load. While data from two weeks after the vaccination series showed promise, participants with Hepatitis...
Former Anti-Itch Drug Useful Against Hep C
California scientists have found that an old antihistamine drastically reduces Hepatitis C viral replication....
Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...
|
|
|
|
Hepatitis C Virus Dynamics In Vivo:
Effect of Ribavirin and Interferon Alfa on Viral
Turnover
table 1.
Demographic, Biochemical, Serological, and Histological Profile of
Patients With Chronic Hepatitis C Treated With
3 × 3 MU rIFN- , 3 × 6 MU rIFN-,, or 3 × 6 MU
rIFN-, Per Week Plus
Ribavirin (14 mg/kg of body weight per day) |
|
| Characteristics |
3 × 3 MU rIFN-![]() =
SRC="b_alpha.gif"> (N = 26) |
3 × 6 MU rIFN-![]() =
SRC="b_alpha.gif"> (N = 19) |
3 × 6 MU rIFN-![]() =
SRC="b_alpha.gif"> + ribavirin (N = 18) |
|
| Age (yr) |
44 ± 13 |
43 ± 12 |
40 ± 11 |
| Sex (M/F) |
16/10 |
12/7 |
11/7 |
| Genotype |
| HCV-1 |
17 |
12 |
11 |
| HCV-2 |
6 |
2 |
4 |
| HCV-3 |
3 |
5 |
3 |
| Pretreatment HCV RNA+ |
5.0 × 106 |
3.8 × 106 |
6.5 × 106 |
|
(0.15-100 × 106) |
(0.56-13 × 106) |
(0.24-38 × 106) |
| Serology |
| Anti-HCV |
26 |
19 |
18 |
| HBsAg |
0 |
0 |
0 |
| Anti-HBc |
7 |
9 |
6 |
| Anti-HIV |
0 |
0 |
0 |
| Laboratory data |
| ALT (U/L) |
79.3 ± 45.4 |
76.4 ± 47.2 |
53.1 ± 32.8 |
| AST (U/L) |
41.3 ± 30.8 |
40.3 ± 20.3 |
31.6 ± 20.7 |
| Bilirubin (µmol/L) |
11.3 ± 3.6 |
9.4 ± 7.8 |
10.5 ± 3.7 |
| Albumin (g/L) |
44 ± 9 |
49 ± 3 |
50 ± 3 |
 -Globulin (g/L) |
16 ± 5 |
15 ± 4 |
16 ± 5 |
| Liver histology |
| Minimal activity |
4 |
3 |
7 |
| Moderate activity |
14 |
6 |
5 |
| Severe activity |
5 |
9 |
2 |
| Active cirrhosis |
3 |
1 |
4 |
| Initial decline of HCV RNA below
detection limit
(genotype HCV-1, -2, -3)
|
10/26 (4, 4, 2) |
10/19 (4, 2, 4) |
10/18 (4, 4, 2) |
|
Return To Article
Copyright © 1998 by the American Association for the Study
of Liver Diseases.
|
|
|
